AlphAIAlphAI — Financial news for AI agents
tradingview.com

CorMedix Therapeutics Gets FDA Priority Review for REZZAYO sNDA

CorMedix Therapeutics announced the FDA accepted and granted Priority Review for its supplemental New Drug Application (sNDA) for REZZAYO, aiming to prevent invasive fungal disease. The Prescription Drug User Fee Act (PDUFA) target action date is set for Q1 2027, according to the company.

Original reporting
tradingview.com
Published Oct 19, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 11:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CorMedix Therapeutics Gets FDA Priority Review for REZZAYO sNDA — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The priority review could accelerate market entry for REZZAYO as a prophylactic, influencing valuation and sector sentiment.

02

Market read

Regulatory milestone may drive short-term price movement and long-term upside if approval is secured.

03

What to watch

Competing prophylactic agents and reimbursement uncertainties.

Relevance 8/10Novelty 8/10Timing: future (Q1 2027 PDUFA target)

Background

CorMedix Therapeutics announced FDA acceptance of its supplemental NDA for REZZAYO, granting priority review with a PDUFA target date in Q1 2027.

Market effects

Sector

Potential boost to antifungal biotech sector if approval granted.

Regional

Limited to US biotech investors.

Global

Modest; primarily affects niche therapeutic market.

Counterpoint

What could challenge this read

Approval risk remains high; market may have priced in optimism.

Key entities

  • Company
    CorMedix Therapeutics

    Biotech developer of REZZAYO.

  • Regulatory Agency
    FDA

    U.S. Food and Drug Administration granting priority review.

Read at source← All news

StoryCorMedix receives FDA priority review for REZZAYO prophylaxis sNDA

Also covered by

5 outlets

Related articles

$CRMDMedAI 8/10

CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position Parsippany, NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call ex

SEC EDGAR 8-K
$CRMDMed

CorMedix reports $355M cash, reaffirms 2026 revenue guidance

CorMedix (CRMD) reported $355M in cash as of September 30 and reaffirmed its 2026 revenue guidance of $325M-$345M. The CMS set a Q1 2027 Add-on payment for DefenCath at $8.32 per session, within the company's guided range. CorMedix expects the Add-on to decline in Q2 2027 but increase in Q3 and Q4, with the average rate exceeding 2x the current rate. The company plans to discuss financial results on November 12, 2026.

investing.com
$CRMDMed

A federal rule sets an $8.32 add-on payment per DefenCath dialysis session in Q1 2027.

CorMedix Therapeutics (CRMD) reported $355M in cash reserves as of Q3 2026 and reaffirmed its 2026 revenue guidance of $325M-$345M. CMS set an $8.32 Add-on payment per DefenCath dialysis session for Q1 2027, within CorMedix's guided range. The company expects the Add-on to decline in Q2 2027 but increase in later quarters, with an average rate exceeding 2x the current $2.37. CorMedix will discuss its Q3 financial results on November 12, 2026.

stocktitan.net
$CRMDMedAI 8/10

CorMedix Gains FDA Priority Review For REZZAYO's Potential New Indication

CorMedix (CRMD) and Mundipharma's REZZAYO (rezafungin) received FDA Priority Review for preventing invasive fungal diseases. The sNDA is based on the Phase 3 ReSPECT study, with a target action date in Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis. If approved, CorMedix plans to start promotions in H2 2027. CRMD stock is up 0.55% in pre-market trading.

rttnews.com
$CRMDMedAI 8/10

CorMedix Wins Priority Review For REZZAYO SNDA In Fungal Disease Prevention

CorMedix (CRMD) announced the FDA accepted its sNDA for REZZAYO (rezafungin) to prevent fungal diseases, granting Priority Review. The application, submitted by partner Mundipharma, is based on a Phase 3 trial. The FDA set a target action date for Q1 2027. REZZAYO is currently approved for treating candidemia and invasive candidiasis in certain patients. The stock was up 0.55% in pre-market trading.

rttnews.com